Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus LOTEPREDNOL ETABONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus LOTEPREDNOL ETABONATE.
CORTIFOAM vs LOTEPREDNOL ETABONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Corticosteroid with high glucocorticoid receptor affinity; reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
0.5% ophthalmic suspension: 1-2 drops into affected eye(s) four times daily. In severe cases, may be increased to 1-2 drops every hour during the first week, then taper.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Terminal elimination half-life is 2.2-4.3 hours; clinical context: supports twice-daily dosing in ophthalmic use, with minimal systemic accumulation.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Primarily hepatic metabolism; metabolites excreted in urine (approximately 80% as inactive metabolites) and feces (15-20%). Less than 1% excreted unchanged in urine.
Category C
Category C
Corticosteroid
Corticosteroid